• Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
  • Industry
  • Finance
  • Culture
  • Politics
  • Science
  • Wellness
AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy
Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy
Two New Studies Are Rewriting the Rules of Psychedelic Drug Development
Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative
Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward
Delix Therapeutics Reports Strong Phase Ib Results
Childhood Trauma’s Role in Men’s Substance Use Disorders
Human-Centered AI in Healthcare
Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up
The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch
Shop

ATAI Files For Potential $300M Capital Raise

Jason Najum by Jason Najum
July 6, 2022
in Industry
Reading Time: 2 mins read
A A
ATAI Files For Potential $300M Capital Raise

 

This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission, or the SEC, using a “shelf” registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a total dollar amount of $300,000,000 as described in this prospectus.

That was the language of the shelf prospectus filed a few days ago by atai Life Sciences. A shelf offering allows a company to register a new batch of shares without having to sell the entire issue at once, allowing them the option to raise capital over a three-year period. This gives the company flexibility to act quickly if a good opportunity arises, without having to re-register with the regulators and go through the review process.

You might ask why atai, the most cash-heavy gang in the business, would want to raise another $300 million right now (especially considering how low stock prices are at the moment).

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Continue on your trip...

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

 

Well, first of all, this doesn’t mean they’ll actually raise the full amount, or even any of it. There’s no obligation here. But it does give us a chance to review the company’s situation.

According to atai’s most recent financials

Purchase Premium Lasix

 “atai ended the year with a strong cash position of $362 million which it anticipates will be sufficient to provide a cash runway of approximately two years, including funding of additional anticipated business development activity.”

But they already have 12 active programs with plans to increase the number to 14, and with most of them still in preclinical and advanced (and more expensive) Phase 2 trials starting this year, we can expect burn rates to really start increasing (net loss was approx $170 million last year without a Phase 2 trial underway).

So is this just some very pre-empitve pre-planning? Or is there something else to be gleaned from this move? Do they expect positive news or trial results to be coming and want to be able to act fast? Or perhaps just sending some signls/reminders to the market about the size of their wallet and position as cash king?

Speculation, speculation. We’ll be watching for more concrete moves and keep you updated.

 

[bsa_pro_ad_space id=2]
ADVERTISEMENT

Interested in more like this? Check out ATAI Announces Fourth Quarter and Full Year 2021 Results

Tags: ATAI Life Sciences
Jason Najum

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Next Post
A Look at Psychedelics in the Media

A Look at Psychedelics in the Media

Please login to join discussion

Who do you think will be first to successfully develop a psychedelic drug?
This field is for validation purposes and should be left unchanged.

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

ADVERTISEMENT

Follow us on social

Microdose is your guide to psychedelics. Our mission is to shift the world’s perception of psychedelic medicine.

Read the News
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
  • Industry
  • Culture
  • Science
  • Finance
  • Law & Politics
  • Health & Wellness
Online Courses
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
  • Microdosing
  • MDMA
  • Ketamine
  • Psychedelic Counseling
  • Addiction Treatment
  • Classic Psychedelics
Subscribe for Exclusive Updates

Terms & Conditions / Privacy Policy

© 2026 MD Media Inc. All rights reserved. The information provided on this website does not, and is not intended to, constitute financial, legal or medical advice. All information, content, and materials available on this site are for general educational and informational purposes only.

WordPress Ads
No Result
View All Result
  • Landing Page
  • Buy JNews
  • Support Forum
  • Contact Us

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.